

J Leinonen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/10888025/j-leinonen-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

34
papers

2,135
citations

21
h-index

35
g-index

35
ext. papers

2,286
ext. citations

5.6
avg. IF

3.93
L-index

#	Paper	IF	Citations
34	First observations of triple-frequency radar Doppler spectra in snowfall: Interpretation and applications. <i>Geophysical Research Letters</i> , 2016 , 43, 2225-2233	4.9	30
33	Performance assessment of a triple-frequency spaceborne cloud precipitation radar concept using a global cloud-resolving model. <i>Atmospheric Measurement Techniques</i> , 2015 , 8, 3493-3517	4	14
32	What do triple-frequency radar signatures reveal about aggregate snowflakes?. <i>Journal of Geophysical Research D: Atmospheres</i> , 2015 , 120, 229-239	4.4	42
31	Linking snowflake microstructure to multi-frequency radar observations. <i>Journal of Geophysical Research D: Atmospheres</i> , 2013 , 118, 3259-3270	4.4	23
30	Evidence of nonspheroidal behavior in millimeter-wavelength radar observations of snowfall. <i>Journal of Geophysical Research</i> , 2012 , 117, n/a-n/a		51
29	Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland. <i>Journal of Urology</i> , 2001 , 166, 2189-91; discussion 2191-2	2.5	42
28	Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. <i>FEBS Journal</i> , 2000 , 267, 6212-20		59
27	Reduced stability of prostate-specific antigen after long-term storage of serum at -20 degrees C. <i>Tumor Biology</i> , 2000 , 21, 46-53	2.9	7
26	Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. <i>Urology</i> , 2000 , 56, 267-72	1.6	36
25	Prostate-specific antigen and other prostate cancer markers. <i>Urology</i> , 2000 , 56, 893-8	1.6	22
24	Development of novel peptide ligands modulating the enzyme activity of prostate-specific antigen. <i>Scandinavian Journal of Clinical and Laboratory Investigation, Supplement</i> , 2000 , 233, 59-64		1
23	Reactivity of 77 antibodies to prostate-specific antigen with isoenzymes and complexes of prostate-specific antigen. <i>Tumor Biology</i> , 1999 , 20 Suppl 1, 28-34	2.9	11
22	Reactivity of anti-PSA monoclonal antibodies with recombinant human kallikrein-2. <i>Tumor Biology</i> , 1999 , 20 Suppl 1, 35-7	2.9	5
21	Prostate-specific antigen. <i>Seminars in Cancer Biology</i> , 1999 , 9, 83-93	12.7	128
20	Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigen. <i>Tumor Biology</i> , 1999 , 20 Suppl 1, 1-12	2.9	57
19	Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. <i>Clinical Chemistry</i> , 1999 , 45, 814-21	5.5	12
18	The clinical importance of free prostate-specific antigen (PSA). <i>Current Opinion in Urology</i> , 1998 , 8, 393-92.8		10

17	Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. <i>Clinical Chemistry</i> , 1998 , 44, 2471-9	5.5	12
16	Activation of type IV procollagenases by human tumor-associated trypsin-2. <i>Journal of Biological Chemistry</i> , 1997 , 272, 21067-74	5.4	155
15	Prostate-specific antigen forms a complex with and cleaves alpha 1-protease inhibitor in vitro. <i>Prostate</i> , 1997 , 33, 87-96	4.2	38
14	Significance of free and bound prostate-specific antigen. <i>Endocrine-Related Cancer</i> , 1996 , 3, 191-197	5.7	1
13	Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland. <i>British Journal of Cancer</i> , 1996 , 74, 568-72	8.7	23
12	Serum complex of trypsin 2 and alpha 1 antitrypsin as diagnostic and prognostic marker of acute pancreatitis: clinical study in consecutive patients. <i>BMJ: British Medical Journal</i> , 1996 , 313, 333-7		66
11	Complex formation between PSA isoenzymes and protease inhibitors. <i>Journal of Urology</i> , 1996 , 155, 1099-103	2.5	10
10	Detection of prostatic cells in peripheral blood: correlation with serum concentrations of prostate-specific antigen. <i>Clinical Chemistry</i> , 1995 , 41, 182-186	5.5	58
9	Standardization of PSA determinations. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1995 , 221, 45-51	2	14
8	Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. <i>Clinical Chemistry</i> , 1995 , 41, 1567-73	5.5	37
7	Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. <i>Clinical Chemistry</i> , 1995 , 41, 1567-1573	5.5	129
6	Time-resolved immunofluorometric assay of trypsin-2 complexed with alpha 1-antitrypsin in serum. <i>Clinical Chemistry</i> , 1994 , 40, 1761-1765	5.5	37
5	Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. <i>Lancet, The</i> , 1994 , 344, 1594-8	4.0	214
4	Time-resolved immunofluorometric assay of trypsin-2 complexed with alpha 1-antitrypsin in serum. <i>Clinical Chemistry</i> , 1994 , 40, 1761-5	5.5	7
3	Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. <i>Clinical Chemistry</i> , 1993 , 39, 2098-2103	5.5	126
2	Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. <i>Clinical Chemistry</i> , 1993 , 39, 2098-103	5.5	19
1	A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. <i>Cancer Research</i> , 1991 , 51, 222-6	10.1	639